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In addition and from a biochemical perspective, posttranslational modifications of PPARg have been identified and characterized, which include phosphorylation, ubiquitination and sumoylation. These changes after the translation of the protein determine the transcriptional output of the receptor. 5, 6 Nonetheless, key issues such as the identity of endogenous ligands driving the activity of the receptor and critical cofactors and other protein-protein interactions determining cell and gene selective activity remain largely unknown. Also additional essential biochemical processes required for proper function of the receptor are not well characterized.
A study in this issue from S + oti and colleagues 7 goes to some distance in filling this gap by uncovering a potential link between PPARg and its role in adipocyte differentiation and chaperones.
Molecular chaperones are ubiquitous and well-conserved proteins, which contribute to the essential machinery that binds to other proteins termed clients to support them in the folding process and preserve their conformation. Also known as Heatshock proteins (Hsp), because of their property to be inducible in response to a stress stimulus, they also have physiological roles in a variety of processes. 8, 9 As far as adipocytes are concerned, chaperones have been implicated in the generation of proinflammatory mediators in adipocytes. 10 There are also studies linking chaperones, heat shock and metabolism. 11 As a surprising example of such connections, a relatively small study in Type 2 Diabetes patients showed that hot-tub therapy improves glycemic control. 12 Also, in an in vivo murine model heat treatment can prevent skeletal muscle insulin resistance and stress kinase activation. 13 Altered concentration of chaperones Hsp70, Hsp 72 and Hsp90 in plasma, liver and pancreas was found in an animal model of diabetes. 14, 15 These studies collectively suggest that there might be links between chaperone function and metabolic regulation. This connection is strengthened by this new report.
The authors in this study use pharmacological inhibitors and show that an N-terminal Hsp90 inhibitor (geldanamycin) impairs the adipocyte differentiation in the widely used 3T3-L1 model. Importantly, this inhibitor and another C-terminal inhibitor (novobiocin) also deplete PPARg protein levels. The doses used in these experiments were below the levels affecting cell survival. Next, the authors could show that PPARg interacts with Hsp90b in 3T3-L1-derived adipocytes and when treated with geldanamycin the receptor is degraded via the proteosomal pathway. Finally, the authors document that the inhibition of Hsp90 affects PPARg-driven downstream events and that this chaperone also stabilizes PPARg in mature 3T3-L1 derived adipocytes and that proteotoxic stress including heat shock and proteasome inhibition alters the PPARg and Hsp90 complex, leading to impaired adipocyte differentiation at least in this model (Figure 1 ). The authors put forward the hypothesis that PPARg chaperoning might be involved in energy store variations, because Hsp90 is capable to sense ADP/ATP ratio and ATP reduction causes the rupture of Hsp90 and its clients. This is an interesting new development. However, there are many questions remain to be answered. Although the authors show interaction of the molecular chaperone Hsp90 with PPARg, there are other Hsp90 'clients' that could contribute to the effect of its inhibition in adipocyte differentiation. 16, 17 Such a scenario cannot be excluded at this point. Further genetic and biochemical data are also needed to establish the molecular details of Hsp90-PPARg interaction and how it plays into the interaction of the receptor and co-activators and corepressors.
Increased body weight and obesity are major public health issues and recently became important foci for research, especially due to the fact that the adipose tissue now has been recognized as an active endocrine organ. Therefore, the unbalance in its physiological function can potentially lead to or maintain numerous comorbidities. It is not unreasonable for the authors to suggest the use of geldanamycin in obesity and related metabolic complications, based on these findings. However, caution is needed to be exercised due to the lack of in vivo data supporting the claims and because Hsp inhibitors have been developed as anticancer drugs and that additional Hsp90 clients are also likely to be involved in various important physiological process. 10 It could be potentially more promising to target the proposed specific interaction between Hsp90 and PPARg. It would also be useful to use more system level analyses in determining the protein-protein interaction network of key transcription factors such as PPARg to identify novel interactions also amenable for pharmacological intervention.
